For US Healthcare Professionals

Sotalol IV Logo

Steinberg BA, Deering TF, Holubkov R, et al. Expedited Loading with Intravenous Sotalol and Mobile ECG Monitoring – Primary Results of the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry. Poster Presented at Heart Rhythm Society 2023; May 19 -21, 2023; New Orleans, LA.

In their poster presented at the Heart Rhythm Society 2023 meeting in New Orleans, Dr. Steinberg et al provided an overview of the results of the PEAKS Sotalol IV registry.  In that multicenter, prospective evaluation of 151 patients, which included pharmacokinetics / pharmacodynamics profiles and mobile ECG monitoring, the mean length of stay was 0.8 days. Sotalol IV was viewed as safe and feasible, with low rates of adverse events and shortened length of hospitalization.

Steinberg BA, Deering TF, Holubkov R, et al. Expedited Loading with Intravenous Sotalol and Mobile ECG Monitoring – Primary Results of the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry. Poster Presented at Heart Rhythm Society 2023; May 19 -21, 2023; New Orleans, LA.
PEAKS poster (Steinberg et al) presented at HRS 2023.

Highlights of Prescribing Information

Boxed Warning, Indications, and Important Safety Information

WARNING: LIFE THREATENING PROARRHYTHMIA

Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation. To minimize the risk of drug induced arrhythmia, initiate or uptitrate intravenous sotalol in a facility that can provide continuous electrocardiographic monitoring and cardiac resuscitation [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)].
Do not initiate intravenous sotalol therapy if the baseline QTc is longer than 450 ms. If the QTc prolongs to 500 ms or greater, reduce the dose or discontinue. (2.3)